Status:
COMPLETED
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
Pancreatic Cancer
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic cancer is a highly lethal disease. The cause of pancreatic cancer is multifactorial. However, around 10% of cases are associated with hereditary predisposition. Germline mutations in BRCA1 ...
Detailed Description
This is an observational study to estimate the prevalence of germline mutations in patients with pancreatic cancer. Eighty four genes will be analyzed, all of which have been associated with hereditar...
Eligibility Criteria
Inclusion
- Female and male participants ≥ 18 years of age.
- Diagnosed within the previous 6 months with histologically confirmed pancreatic adenocarcinoma stage I to IV.
- Participant provides written informed consent for the study.
- Participant must agree to sample collection and genetic testing using the Invitae Multi-Cancer Panel ®.
Exclusion
- Diagnosed with pancreatic adenocarcinoma more than 6 months before presenting to the clinical site.
- Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors.
Key Trial Info
Start Date :
September 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT05305001
Start Date
September 9 2020
End Date
June 30 2022
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico, 14080